Benjamin E Zusman1,2,3, Patrick M Kochanek3,4,5,6,7,8, Ruchira M Jha3,7,8,9,10. 1. University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 2. Institute for Clinical Research Education, University of Pittsburgh, Pittsburgh, PA, USA. 3. Clinical and Translational Science Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 4. Department of Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 5. Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 6. UPMC Children's Hospital of Pittsburgh, UPMC, Pittsburgh, PA, USA. 7. Department of Critical Care Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 8. Safar Center for Resuscitation Research, John G. Rangos Research Center, Pittsburgh, PA, USA. 9. Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. 10. Department of Neurological Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Abstract
PURPOSE OF REVIEW: The purposes of this narrative review are to (1) summarize a contemporary view of cerebral edema pathophysiology, (2) present a synopsis of current management strategies in the context of their historical roots (many of which date back multiple centuries), and (3) discuss contributions of key molecular pathways to overlapping edema endophenotypes. This may facilitate identification of important therapeutic targets. RECENT FINDINGS: Cerebral edema and resultant intracranial hypertension are major contributors to morbidity and mortality following traumatic brain injury. Although Starling forces are physical drivers of edema based on differences in intravascular vs extracellular hydrostatic and oncotic pressures, the molecular pathophysiology underlying cerebral edema is complex and remains incompletely understood. Current management protocols are guided by intracranial pressure measurements, an imperfect proxy for cerebral edema. These include decompressive craniectomy, external ventricular drainage, hyperosmolar therapy, hypothermia, and sedation. Results of contemporary clinical trials assessing these treatments are summarized, with an emphasis on the gap between intermediate measures of edema and meaningful clinical outcomes. This is followed by a brief statement summarizing the most recent guidelines from the Brain Trauma Foundation (4th edition). While many molecular mechanisms and networks contributing to cerebral edema after TBI are still being elucidated, we highlight some promising molecular mechanism-based targets based on recent research including SUR1-TRPM4, NKCC1, AQP4, and AVP1. SUMMARY: This review outlines the origins of our understanding of cerebral edema, chronicles the history behind many current treatment approaches, and discusses promising molecular mechanism-based targeted treatments.
PURPOSE OF REVIEW: The purposes of this narrative review are to (1) summarize a contemporary view of cerebral edema pathophysiology, (2) present a synopsis of current management strategies in the context of their historical roots (many of which date back multiple centuries), and (3) discuss contributions of key molecular pathways to overlapping edema endophenotypes. This may facilitate identification of important therapeutic targets. RECENT FINDINGS: Cerebral edema and resultant intracranial hypertension are major contributors to morbidity and mortality following traumatic brain injury. Although Starling forces are physical drivers of edema based on differences in intravascular vs extracellular hydrostatic and oncotic pressures, the molecular pathophysiology underlying cerebral edema is complex and remains incompletely understood. Current management protocols are guided by intracranial pressure measurements, an imperfect proxy for cerebral edema. These include decompressive craniectomy, external ventricular drainage, hyperosmolar therapy, hypothermia, and sedation. Results of contemporary clinical trials assessing these treatments are summarized, with an emphasis on the gap between intermediate measures of edema and meaningful clinical outcomes. This is followed by a brief statement summarizing the most recent guidelines from the Brain Trauma Foundation (4th edition). While many molecular mechanisms and networks contributing to cerebral edema after TBI are still being elucidated, we highlight some promising molecular mechanism-based targets based on recent research including SUR1-TRPM4, NKCC1, AQP4, and AVP1. SUMMARY: This review outlines the origins of our understanding of cerebral edema, chronicles the history behind many current treatment approaches, and discusses promising molecular mechanism-based targeted treatments.
Authors: Christopher Galton; Steven Deem; N David Yanez; Michael Souter; Randall Chesnut; Armagan Dagal; Miriam Treggiari Journal: Neurocrit Care Date: 2011-06 Impact factor: 3.210
Authors: Bizhan Aarabi; Dale C Hesdorffer; Edward S Ahn; Carla Aresco; Thomas M Scalea; Howard M Eisenberg Journal: J Neurosurg Date: 2006-04 Impact factor: 5.115
Authors: Kevin N Sheth; Jordan J Elm; Bradley J Molyneaux; Holly Hinson; Lauren A Beslow; Gordon K Sze; Ann-Christin Ostwaldt; Gregory J Del Zoppo; J Marc Simard; Sven Jacobson; W Taylor Kimberly Journal: Lancet Neurol Date: 2016-08-23 Impact factor: 44.182
Authors: Ruchira M Jha; Anupama Rani; Shashvat M Desai; Sudhanshu Raikwar; Sandra Mihaljevic; Amanda Munoz-Casabella; Patrick M Kochanek; Joshua Catapano; Ethan Winkler; Giuseppe Citerio; J Claude Hemphill; W Taylor Kimberly; Raj Narayan; Juan Sahuquillo; Kevin N Sheth; J Marc Simard Journal: Int J Mol Sci Date: 2021-11-02 Impact factor: 5.923